Friday - May 10, 2024
AstraZeneca Announces Initiation of Tharros - A Phase III Clinical Trial Investigating the Potential of Breztri to Improve Cardiopulmonary Outcomes in People With COPD
March 16, 2024
WILMINGTON, Delaware, March 16 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on March 13, 2024:

AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE(R) (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes, including death*, in people with chronic obstructive pulmonary disease (COPD) who also have eleva . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products